<DOC>
	<DOCNO>NCT01476280</DOCNO>
	<brief_summary>Ramosetron palonosetron recently develop 5-hydroxytryptamine type 3 receptor antagonist randomize double blind study design compare efficacy ramosetron palonosetron prevent postoperative nausea vomit . Investigator hypothesize palonosetron would stronger long last antiemetic effect compare ramosetron evaluate patient first 48 hour surgery .</brief_summary>
	<brief_title>Palonosetron Versus Ramosetron Prevention Postoperative Nausea Vomiting</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Postoperative Nausea Vomiting</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<mesh_term>Ramosetron</mesh_term>
	<criteria>ASA Physical Status 1 2 Elective gynaecological laparoscopic surgery â‰¥ 1h duration Antiemetics , steroid , psychoactive medication within 24 h study initiation Vomiting retch 24 h precede surgery Cancer chemotherapy within 4 week emetogenic radiotherapy within 8 week study entry Ongoing vomit gastrointestinal disease</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>antiemetic</keyword>
	<keyword>ramosetron</keyword>
	<keyword>palonosetron</keyword>
	<keyword>PONV ( postoperative nausea vomit )</keyword>
</DOC>